Precigen’s Experimental RRP Treatment Shows Early Signs of Promise

Published on :

In January, the Germantown-based company announced positive data from a Phase I dose escalation and expansion cohort for the potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse. Data shared by Precigen during its R&D Day presentation showed treatment with PRGN-2012 significantly reduced the need for surgeries for severe, aggressive RRP patients who received Dose Level 2 of the medication.

Weekly Quick Hits (BioHealth Capital Region) – Week of January 23, 2023

Published on :

Here’s what’s been happening the BioHealth Capital Region’s Life Science scene the week of January 23, 2023

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Published on :

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive Phase 1 dose escalation data from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with r/r AML and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract# 4633). The presentation was delivered by David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute (Moffitt) and a lead investigator for the PRGN-3006 clinical trial.

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

Published on :

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023. Consummation of the transaction, anticipated in Q3 2022, is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

5 Questions With Surya Sundar, Ph.D., Business Development Analyst at Precigen

Published on :

Surya is currently a Business Development Analyst at Precigen, a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. His role is to facilitate strategic partnerships with key stakeholders; assist in drafting proposals, contracts, and marketing content; track key industry trends; portfolio management; and competitive intelligence. Essentially, he provides industry context to the R&D activities that are ongoing at Precigen to help leadership make strategic decisions with potential partners. 

Precigen UltraCAR-T Technology Flexes its Muscles at ASH Meeting

Published on :

At the American Society of Hematology meeting earlier this month, Precigen presented positive interim data from an ongoing Phase 1/2b clinical study of PRGN-3006 UltraCAR-T in patients who have been diagnosed with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). The interim study data showed what the trial investigators are calling “excellent, dose-dependent expansion.”

Forbes 50 Over 50 Female Visionaries: Two MD Biotech CEOs Honored

Forbes recently honored two Maryland biotech CEOs
Published on :

Forbes recently honored two Maryland biotech CEOs, naming them to the 50 Over 50 list of female visionaries. The local awardees are Helen Sabzevari of Precigen and Carol Nacy of Sequella. Sabzevari focuses on cancer treatment, and Nacy battles tuberculosis.